UNSPSC 51401565: Loprazolammesilate or mesylate

This classification denotes a benzodiazepine with the molecular formula C23H21ClN6O3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VKF8383J65, chemically known as 1h-imidazo(1,2-a)(1,4)benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-((4-methyl-1-piperazinyl)methylene)-8-nitro-, (2z)-, methanesulfonate (1:1), but more generally known as loprazolam mesylate, which bears US NIH Compound Identifier 6917853.

European Medicines Agency schedules loprazolam mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08576MIG. Most nations, for tariff purposes, schedule loprazolam mesylate under HS 29335500. SMILES: CN1CCN(CC1)/C=C\2/C(=O)N3C4CCC(CC4C(=NCC3=N2)C5CCCCC5CL)[N+](=O)[O-].CS(=O)(=O)O.

UNSPSC 51401565 Loprazolammesilate or mesylate is a Commodity code whose recent tagging by state and local procurement offices shows a mismatch with the code's pharmaceutical-chemical scope. The single opportunity explicitly tagged to this code—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—involves naloxone (an opioid antagonist), not loprazolammesilate (a benzodiazepine). The two other recent opportunities in the dataset—the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions and the Minnesota MMCAP's RFP for generic multi-source pharmaceuticals—cover broader pharmaceutical procurement but do not reference loprazolammesilate or benzodiazepine products by name. The code shows little relevant recent activity when filtered for the actual pharmaceutical product it nominally covers.

The Seminole County opportunity, posted June 30, 2026, with a response deadline of July 26, 2023 (a historical date inconsistent with the posting date), required 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the county's Community Health Building in Sanford, Florida, with all shipping costs vendor-funded. The Texas and Minnesota opportunities represent broader state-level cooperative and direct pharmaceutical procurement efforts, not category-specific purchases. No issuing body has solicited loprazolammesilate specifically in the recent records, and no geographic concentration or repeat-buyer pattern emerges for this commodity code.